<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36614231</PMID><DateCompleted><Year>2023</Year><Month>01</Month><Day>10</Day></DateCompleted><DateRevised><Year>2023</Year><Month>01</Month><Day>11</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1422-0067</ISSN><JournalIssue CitedMedium="Internet"><Volume>24</Volume><Issue>1</Issue><PubDate><Year>2023</Year><Month>Jan</Month><Day>02</Day></PubDate></JournalIssue><Title>International journal of molecular sciences</Title><ISOAbbreviation>Int J Mol Sci</ISOAbbreviation></Journal><ArticleTitle>Thermodynamic Signatures of Blood Plasma Proteome in Neurodegenerative Pathologies.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">789</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/ijms24010789</ELocationID><Abstract><AbstractText>Discovery of diagnostic biomarkers for age-related neurodegenerative pathologies (NDDs) is essential for accurate diagnosis, following disease progression and drug development. Blood plasma and blood cells are important peripheral sources for NDDs' biomarkers that, although present in lower concentrations than in cerebrospinal fluid, would allow noninvasive diagnostics. To identify new biomarkers for Parkinson's disease (PD) and amyotrophic lateral sclerosis (ALS), in this work we have evaluated the modifications in the thermodynamic behavior of blood plasma proteome exploring differential scanning calorimetry. The plasma thermodynamics reflected the complexity and heterogeneity of the two pathologies. The unfolding temperature of the most abundant plasma protein albumin and the weighted average center of the calorimetric profile appeared as the two thermodynamic signatures that reflected modifications of the plasma proteome, i.e., strong thermal stabilization of albumin and plasma proteins' interaction network, related to both pathologies. Based on those two signatures, both PD and ALS patients were stratified in two sets, except several cases with thermodynamic parameters that strongly differed from those of the calorimetric sets. Along with modifications of the plasma thermodynamic behavior, we found altered globulin levels in all PD and ALS patients' plasma (higher level of &#x3b1;- and &#x3b2;-globulin fractions and lower level of &#x3b3;-globulin fraction than the respective reference values) employing capillary electrophoresis. The presented results reveal the potential of calorimetry to indirectly identify NDDs' biomarkers in blood plasma.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Danailova</LastName><ForeName>Avgustina</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Institute of Biophysics and Biomedical Engineering, Bulgarian Academy of Sciences, "Acad. G. Bonchev" Str. 21, 1113 Sofia, Bulgaria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Todinova</LastName><ForeName>Svetla</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0001-7108-051X</Identifier><AffiliationInfo><Affiliation>Institute of Biophysics and Biomedical Engineering, Bulgarian Academy of Sciences, "Acad. G. Bonchev" Str. 21, 1113 Sofia, Bulgaria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gartcheva</LastName><ForeName>Lidia</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>National Specialized Hospital for Active Treatment of Haematological Diseases, "Plovdivsko pole" Str. 6, 1756 Sofia, Bulgaria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bogdanova</LastName><ForeName>Desislava</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>University Multiprofile Hospital for Active Treatment in Neurology and Psychiatry "St. Naum", "Louben Roussev" Str. 1, 1113 Sofia, Bulgaria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zlatareva</LastName><ForeName>Elena</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>University Multiprofile Hospital for Active Treatment in Neurology and Psychiatry "St. Naum", "Louben Roussev" Str. 1, 1113 Sofia, Bulgaria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kalaydzhiev</LastName><ForeName>Nikolay</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>University Multiprofile Hospital for Active Treatment in Neurology and Psychiatry "St. Naum", "Louben Roussev" Str. 1, 1113 Sofia, Bulgaria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Milanov</LastName><ForeName>Ivan</ForeName><Initials>I</Initials><Identifier Source="ORCID">0000-0002-4522-4070</Identifier><AffiliationInfo><Affiliation>University Multiprofile Hospital for Active Treatment in Neurology and Psychiatry "St. Naum", "Louben Roussev" Str. 1, 1113 Sofia, Bulgaria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Krumova</LastName><ForeName>Sashka</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0001-7412-8398</Identifier><AffiliationInfo><Affiliation>Institute of Biophysics and Biomedical Engineering, Bulgarian Academy of Sciences, "Acad. G. Bonchev" Str. 21, 1113 Sofia, Bulgaria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Taneva</LastName><ForeName>Stefka G</ForeName><Initials>SG</Initials><Identifier Source="ORCID">0000-0001-6851-4516</Identifier><AffiliationInfo><Affiliation>Institute of Biophysics and Biomedical Engineering, Bulgarian Academy of Sciences, "Acad. G. Bonchev" Str. 21, 1113 Sofia, Bulgaria.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>&#x41a;&#x41f;-06-&#x41d;31/8</GrantID><Agency>Bulgarian Science Fund</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>01</Month><Day>02</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Int J Mol Sci</MedlineTA><NlmUniqueID>101092791</NlmUniqueID><ISSNLinking>1422-0067</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D020543">Proteome</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000418">Albumins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020543" MajorTopicYN="N">Proteome</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010949" MajorTopicYN="N">Plasma</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="Y">Parkinson Disease</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000418" MajorTopicYN="N">Albumins</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013816" MajorTopicYN="N">Thermodynamics</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Parkinson&#x2019;s disease</Keyword><Keyword MajorTopicYN="N">amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">blood plasma biomarkers</Keyword><Keyword MajorTopicYN="N">differential scanning calorimetry</Keyword><Keyword MajorTopicYN="N">excess heat capacity</Keyword><Keyword MajorTopicYN="N">globulin fractions</Keyword><Keyword MajorTopicYN="N">thermal transitions</Keyword><Keyword MajorTopicYN="N">transition temperature</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>11</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>12</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>12</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>1</Month><Day>8</Day><Hour>1</Hour><Minute>26</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>1</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>1</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36614231</ArticleId><ArticleId IdType="pmc">PMC9821040</ArticleId><ArticleId IdType="doi">10.3390/ijms24010789</ArticleId><ArticleId IdType="pii">ijms24010789</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Andersen A.D., Binzer M., Stenage E., Gramsberge J.B. Cerebrospinal fluid biomarkers for Parkinson&#x2019;s disease&#x2014;A systematic review. Acta Neurol. Scand. 2017;135:34&#x2013;56. doi: 10.1111/ane.12590.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ane.12590</ArticleId><ArticleId IdType="pubmed">26991855</ArticleId></ArticleIdList></Reference><Reference><Citation>Beach T.G. A review of biomarkers for neurodegenerative disease: Will they swing us across the valley? Neurol. Ther. 2017;6:5&#x2013;13. doi: 10.1007/s40120-017-0072-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40120-017-0072-x</ArticleId><ArticleId IdType="pmc">PMC5520818</ArticleId><ArticleId IdType="pubmed">28733961</ArticleId></ArticleIdList></Reference><Reference><Citation>Meldolesi J. News about the role of fluid and imaging biomarkers in neurodegenerative diseases. Biomedicines. 2021;9:252. doi: 10.3390/biomedicines9030252.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/biomedicines9030252</ArticleId><ArticleId IdType="pmc">PMC7999537</ArticleId><ArticleId IdType="pubmed">33806691</ArticleId></ArticleIdList></Reference><Reference><Citation>Bridel C., van Wieringen W.N., Zetterberg H., Tijms B.M., Teunissen C.E., the NFL Group Diagnostic value of cerebrospinal fluid neurofilament light protein in neurology: A systematic review and meta-analysis. JAMA Neurol. 2019;76:1035&#x2013;1048. doi: 10.1001/jamaneurol.2019.1534.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2019.1534</ArticleId><ArticleId IdType="pmc">PMC6580449</ArticleId><ArticleId IdType="pubmed">31206160</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakamura A., Kaneko N., Villemagne V.L., Kato T., Doecke J., Dor&#xe9; V., Fowler C., Li Q.-X., Martins R., Rowe C., et al. High performance plasma amyloid-&#x3b2; biomarkers for Alzheimer&#x2019;s disease. Nature. 2018;554:249&#x2013;254. doi: 10.1038/nature25456.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature25456</ArticleId><ArticleId IdType="pubmed">29420472</ArticleId></ArticleIdList></Reference><Reference><Citation>Seelaar H., Van Swieten J.C. In vivo PET imaging of neuroinflammation in familial frontotemporal dementia. J. Neurol. Neurosurg. Psychiatry. 2021;92:319&#x2013;322.</Citation><ArticleIdList><ArticleId IdType="pubmed">33361412</ArticleId></ArticleIdList></Reference><Reference><Citation>Hansson O. Biomarkers for neurodegenerative diseases. Nat. Med. 2021;27:954&#x2013;963. doi: 10.1038/s41591-021-01382-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01382-x</ArticleId><ArticleId IdType="pubmed">34083813</ArticleId></ArticleIdList></Reference><Reference><Citation>Olsson B., Lautner R., Andreasson U., &#xd6;hrfelt A., Portelius E., Bjerke M., H&#xf6;ltt&#xe4; M., Ros&#xe9;n C. CSF and blood biomarkers for the diagnosis of Alzheimer&#x2019;s disease: A systematic review and meta-analysis. Lancet Neurol. 2016;15:673&#x2013;684. doi: 10.1016/S1474-4422(16)00070-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(16)00070-3</ArticleId><ArticleId IdType="pubmed">27068280</ArticleId></ArticleIdList></Reference><Reference><Citation>Wojsiat J., Laskowska-Kaszub K., Mietelska-Porowska A., Wojda U. Search for Alzheimer&#x2019;s disease biomarkers in blood cells: Hypotheses-driven approach. Biomark. Med. 2017;11:917&#x2013;931. doi: 10.2217/bmm-2017-0041.</Citation><ArticleIdList><ArticleId IdType="doi">10.2217/bmm-2017-0041</ArticleId><ArticleId IdType="pubmed">28976776</ArticleId></ArticleIdList></Reference><Reference><Citation>Posavi M., Diaz-Ortiz M., Liu B., Swanson C.R., Skrinak R.T., Hernandez-Con P., Amado D.A., Fullard M., Rick J., Siderowf A., et al. Characterization of Parkinson&#x2019;s disease using blood-based biomarkers: A multicohort proteomic analysis. PLoS Med. 2019;16:e1002931. doi: 10.1371/journal.pmed.1002931.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pmed.1002931</ArticleId><ArticleId IdType="pmc">PMC6788685</ArticleId><ArticleId IdType="pubmed">31603904</ArticleId></ArticleIdList></Reference><Reference><Citation>Ashton N.J., Hye A., Rajkumar A.P., Leuzy A., Snowden S., Su&#xe1;rez-Calvet M., Karikari T.K., Sch&#xf6;ll M., La Joie R., Rabinovici G.D., et al. An update on blood-based biomarkers for non-Alzheimer neurodegenerative disorders. Nat. Rev. Neurol. 2020;16:265&#x2013;284. doi: 10.1038/s41582-020-0348-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41582-020-0348-0</ArticleId><ArticleId IdType="pubmed">32322100</ArticleId></ArticleIdList></Reference><Reference><Citation>Strijkova V., Todinova S., Andreeva T., Langari A., Bogdanova D., Zlatareva E., Kalaydzhiev N., Milanov I., Taneva S.G. Platelets&#x2019; Nanomechanics and Morphology in Neurodegenerative Pathologies. Biomedicines. 2022;10:2239. doi: 10.3390/biomedicines10092239.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/biomedicines10092239</ArticleId><ArticleId IdType="pmc">PMC9496241</ArticleId><ArticleId IdType="pubmed">36140340</ArticleId></ArticleIdList></Reference><Reference><Citation>Strijkova-Kenderova V., Todinova S., Andreeva T., Bogdanova D., Langari A., Danailova A., Krumova S., Zlatareva E., Kalaydzhiev N., Milanov I., et al. Morphometry and Stiffness of Red Blood Cells&#x2014;Signatures of Neurodegenerative Diseases and Aging. Int. J. Mol. Sci. 2022;23:227. doi: 10.3390/ijms23010227.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms23010227</ArticleId><ArticleId IdType="pmc">PMC8745649</ArticleId><ArticleId IdType="pubmed">35008653</ArticleId></ArticleIdList></Reference><Reference><Citation>Todinova S., Krumova S., Bogdanova D., Danailova A., Zlatareva E., Kalaydzhiev N., Langari A., Milanov I., Taneva S.G. Red Blood Cells&#x2019; Thermodynamic Behavior in Neurodegenerative Pathologies and Aging. Biomolecules. 2021;11:1500. doi: 10.3390/biom11101500.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/biom11101500</ArticleId><ArticleId IdType="pmc">PMC8534019</ArticleId><ArticleId IdType="pubmed">34680133</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee P.H., Lee G., Park H.J., Bang O.Y., Joo I.S., Huh K. The plasma alpha-synuclein levels in patients with Parkinson&#x2019;s disease and multiple system atrophy. J. Neural. Transm. 2006;113:1435&#x2013;1439. doi: 10.1007/s00702-005-0427-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00702-005-0427-9</ArticleId><ArticleId IdType="pubmed">16465458</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Q.X., Mok S.S., Laughton K.M., McLean C.A., Cappai R., Masters C.L., Culvenor J.G., Horne M.K. Plasma alpha-synuclein is decreased in subjects with Parkinson&#x2019;s disease. Exp. Neurol. 2007;204:583&#x2013;588. doi: 10.1016/j.expneurol.2006.12.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.expneurol.2006.12.006</ArticleId><ArticleId IdType="pubmed">17258710</ArticleId></ArticleIdList></Reference><Reference><Citation>Hong Z., Shi M., Chung K.A., Quinn J.F., Peskind E.R., Galasko D., Jankovic J., Zabetian C.P., Leverenz J.B., Baird G., et al. DJ-1 and alpha-synuclein in human cerebrospinal fluid as biomarkers of Parkinson&#x2019;s disease. Brain. 2010;133:713&#x2013;726. doi: 10.1093/brain/awq008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awq008</ArticleId><ArticleId IdType="pmc">PMC2842513</ArticleId><ArticleId IdType="pubmed">20157014</ArticleId></ArticleIdList></Reference><Reference><Citation>Mollenhauer B., Locascio J.L., Schulz-Schaeffer W., Sixel-D&#xf6;ring F., Trenkwalder C., Schlossmacher M.G. &#x3b1;-synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: A cohort study. Lancet Neurol. 2011;10:230&#x2013;240. doi: 10.1016/S1474-4422(11)70014-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(11)70014-X</ArticleId><ArticleId IdType="pubmed">21317042</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin C.-H., Yang S.-Y., Horng H.-E., Yang C.-C., Chieh J.-J., Chen H.-H., Liu B.-H., Chiu M.-J. Plasma &#x3b1;-synuclein predicts cognitive decline in Parkinson&#x2019;s disease. J. Neurol. Neurosurg. Psychiatry. 2017;88:818&#x2013;824.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5629933</ArticleId><ArticleId IdType="pubmed">28550072</ArticleId></ArticleIdList></Reference><Reference><Citation>Polimeno L., Asabella A.N., Mazzocca A., De Fazio G., Polimeno R., Buquicchio R., Lavelli V., Rubini G. Plasma levels of clusterin are representative of the early phase of the neurodegenerative process in Parkinson&#x2019;s disease. J. Clin. Mol. Med. 2018;1:1&#x2013;5. doi: 10.15761/JCMM.1000102.</Citation><ArticleIdList><ArticleId IdType="doi">10.15761/JCMM.1000102</ArticleId></ArticleIdList></Reference><Reference><Citation>Chio A., Calvo A., Bovio G., Canosa A., Bertuzzo D., Galmozzi F., Cugnasco P., Clerico M., De Mercanti S., Bersano E., et al. Amyotrophic lateral sclerosis outcome measures and the role of albumin and creatinine. JAMA Neurol. 2014;71:1134&#x2013;1142. doi: 10.1001/jamaneurol.2014.1129.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2014.1129</ArticleId><ArticleId IdType="pubmed">25048026</ArticleId></ArticleIdList></Reference><Reference><Citation>Ryberg H., Bowser R. Protein biomarkers for amyotrophic lateral sclerosis. Expert Rev. Proteom. 2008;5:249&#x2013;262. doi: 10.1586/14789450.5.2.249.</Citation><ArticleIdList><ArticleId IdType="doi">10.1586/14789450.5.2.249</ArticleId><ArticleId IdType="pubmed">18466055</ArticleId></ArticleIdList></Reference><Reference><Citation>Turner M.R., Kiernan M.C., Leigh P.N., Talbot K. Biomarkers in amyotrophic lateral sclerosis. Lancet Neurol. 2009;8:94&#x2013;109. doi: 10.1016/S1474-4422(08)70293-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(08)70293-X</ArticleId><ArticleId IdType="pubmed">19081518</ArticleId></ArticleIdList></Reference><Reference><Citation>Quinn J.F., Patel T., Wong D., Das S., Freedman J.E., Laurent L.C., Carter B.S., Hochberg. F., Keuren-Jensen K.V., Huentelman M., et al. Extracellular RNAs: Development as biomarkers of human disease. J. Extracell. Vesicles. 2015;4:27495. doi: 10.3402/jev.v4.27495.</Citation><ArticleIdList><ArticleId IdType="doi">10.3402/jev.v4.27495</ArticleId><ArticleId IdType="pmc">PMC4553262</ArticleId><ArticleId IdType="pubmed">26320940</ArticleId></ArticleIdList></Reference><Reference><Citation>Tokuda T., Qureshi M.M., Ardah M.T., Varghese S., Shehab S.A., Kasai T., Ishigami N., Tamaoka A., Nakagawa M., El-Agnaf O.M. Detection of elevated levels of &#x3b1;-synuclein oligomers in CSF from patients with Parkinson disease. Neurology. 2010;75:1766&#x2013;1772. doi: 10.1212/WNL.0b013e3181fd613b.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0b013e3181fd613b</ArticleId><ArticleId IdType="pubmed">20962290</ArticleId></ArticleIdList></Reference><Reference><Citation>Bruggink K.A., Kuiperij H.B., Ekholm-Pettersson F., Verbeek M.M. Detection of elevated levels of &#x3b1;-synuclein oligomers in CSF from patients with Parkinson disease. Neurology. 2011;77:510. doi: 10.1212/WNL.0b013e318219dd92.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0b013e318219dd92</ArticleId><ArticleId IdType="pubmed">21810701</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang C.-W., Yang S.-Y., Yang C.-C., Chang C.-W., Wu Y.-R. Plasma and serum alpha-synuclein as a biomarker of diagnosis in patients with Parkinson&#x2019;s disease. Front. Neurol. 2020;10:1388. doi: 10.3389/fneur.2019.01388.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fneur.2019.01388</ArticleId><ArticleId IdType="pmc">PMC6990107</ArticleId><ArticleId IdType="pubmed">32038461</ArticleId></ArticleIdList></Reference><Reference><Citation>El-Agnaf O.M., Salem S.A., Paleologou K.E., Curran M.D., Gibson M.J., Court J.A., Schlossmacher M.G., Allsop D. Detection of oligomeric forms of alpha-synuclein protein in human plasma as a potential biomarker for Parkinson&#x2019;s disease. FASEB J. 2006;20:419&#x2013;425. doi: 10.1096/fj.03-1449com.</Citation><ArticleIdList><ArticleId IdType="doi">10.1096/fj.03-1449com</ArticleId><ArticleId IdType="pubmed">16507759</ArticleId></ArticleIdList></Reference><Reference><Citation>Kang J.H., Irwin D.J., Chen-Plotkin A.S., Siderowf A., Caspell C., Coffey C.S., Walig&#xf3;rska T., Taylor P., Pan S., Frasier M., et al. Parkinson&#x2019;s Progression Markers Initiative. Association of cerebrospinal fluid &#x3b2;-amyloid 1-42, T-tau, P-tau181, and &#x3b1;-synuclein levels with clinical features of drug-naive patients with early Parkinson disease. JAMA Neurol. 2013;70:1277&#x2013;1287.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4034348</ArticleId><ArticleId IdType="pubmed">23979011</ArticleId></ArticleIdList></Reference><Reference><Citation>Goedert M. Alzheimer&#x2019;s and Parkinson&#x2019;s diseases: The prion concept in relation to assembled A&#x3b2;, tau, and &#x3b1;-synuclein. Science. 2015;349:1255555. doi: 10.1126/science.1255555.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1255555</ArticleId><ArticleId IdType="pubmed">26250687</ArticleId></ArticleIdList></Reference><Reference><Citation>Iljina M., Dear A.J., Garcia G.A., De S., Tosatto L., Flagmeier P., Whiten D.R., Michaels T.C.T., Frenkel D., Dobson C.M., et al. Quantifying Co-Oligomer Formation by &#x3b1;-Synuclein. ACS Nano. 2018;12:10855&#x2013;10866. doi: 10.1021/acsnano.8b03575.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acsnano.8b03575</ArticleId><ArticleId IdType="pmc">PMC6262461</ArticleId><ArticleId IdType="pubmed">30371053</ArticleId></ArticleIdList></Reference><Reference><Citation>Spires-Jones T.L., Attems J., Thal D.R. Interactions of pathological proteins in neurodegenerative diseases. Acta Neuropathol. 2017;134:187&#x2013;205. doi: 10.1007/s00401-017-1709-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-017-1709-7</ArticleId><ArticleId IdType="pmc">PMC5508034</ArticleId><ArticleId IdType="pubmed">28401333</ArticleId></ArticleIdList></Reference><Reference><Citation>Galpern W.R., Lang A.E. Interface between tauopathies and synucleinopathies: A tale of two proteins. Ann. Neurol. 2006;59:449&#x2013;458. doi: 10.1002/ana.20819.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.20819</ArticleId><ArticleId IdType="pubmed">16489609</ArticleId></ArticleIdList></Reference><Reference><Citation>Hazy E., Bokor M., Kalmar L., Gelencser A., Kamasa P., Han K.H., Tompa K., Tompa P. Distinct hydration properties of wild-type and familial point mutant A53T of &#x3b1;-synuclein associated with Parkinson&#x2019;s disease. Biophys. J. 2011;101:2260&#x2013;2266. doi: 10.1016/j.bpj.2011.08.052.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bpj.2011.08.052</ArticleId><ArticleId IdType="pmc">PMC3207174</ArticleId><ArticleId IdType="pubmed">22067166</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen N.C., Chen H.-L., Li S.-H., Chang Y.-H., Chen M.-H., Tsai N.-W., Yu C.-C., Yang S.-Y., Lu C.-H., Lin W.-C. Plasma levels of &#x3b1;-Synuclein, A&#x3b2;-40 and T-tau as biomarkers to predict cognitive impairment in Parkinson&#x2019;s disease. Front. Aging Neurosci. 2020;12:112. doi: 10.3389/fnagi.2020.00112.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnagi.2020.00112</ArticleId><ArticleId IdType="pmc">PMC7198695</ArticleId><ArticleId IdType="pubmed">32410983</ArticleId></ArticleIdList></Reference><Reference><Citation>Ng A.S.L., Tan Y.J., Yong A.C.W., Saffari S.E., Lu Z., Ng E.Y., Ng S.Y.E., Chia N.S.Y., Choi X., Heng D., et al. Utility of plasma Neurofilament light as a diagnostic and prognostic biomarker of the postural instability gait disorder motor subtype in early Parkinson&#x2019;s disease. Mol. Neurodegener. 2020;15:33. doi: 10.1186/s13024-020-00385-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13024-020-00385-5</ArticleId><ArticleId IdType="pmc">PMC7275464</ArticleId><ArticleId IdType="pubmed">32503574</ArticleId></ArticleIdList></Reference><Reference><Citation>B&#xe4;ckstr&#xf6;m D.C., Eriksson Domell&#xf6;f M., Linder J., Olsson B., &#xd6;hrfelt A., Trupp M., Zetterberg H., Blennow K., Forsgren L. Cerebrospinal fluid patterns and the risk of future dementia in early, incident Parkinson disease. JAMA Neurol. 2015;72:1175&#x2013;1182. doi: 10.1001/jamaneurol.2015.1449.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2015.1449</ArticleId><ArticleId IdType="pubmed">26258692</ArticleId></ArticleIdList></Reference><Reference><Citation>Pilotto A., Imarisio A., Conforti F., Scalvini A., Masciocchi S., Nocivelli S., Turrone R., Gipponi S., Cottini E., Borroni B., et al. Plasma NfL, clinical subtypes and motor progression in Parkinson&#x2019;s disease. Park. Relat. Disord. 2021;87:41&#x2013;47. doi: 10.1016/j.parkreldis.2021.04.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.parkreldis.2021.04.016</ArticleId><ArticleId IdType="pubmed">33964785</ArticleId></ArticleIdList></Reference><Reference><Citation>Yakhine-Diop S.M.S., Morales-Garc&#xed;a J.A., Niso-Santano M., Gonz&#xe1;lez-Polo R.A., Uribe-Carretero E., Martinez-Chacon G., Durand S., Maiuri M.C., Aiastui A., Zulaica M., et al. Metabolic alterations in plasma from patients with familial and idiopathic Parkinson&#x2019;s disease. Aging. 2020;12:16690&#x2013;16708. doi: 10.18632/aging.103992.</Citation><ArticleIdList><ArticleId IdType="doi">10.18632/aging.103992</ArticleId><ArticleId IdType="pmc">PMC7521510</ArticleId><ArticleId IdType="pubmed">32903216</ArticleId></ArticleIdList></Reference><Reference><Citation>Cipriani S., Chen X., Schwarzschild M.A. Urate: A novel biomarker of Parkinson&#x2019;s disease risk, diagnosis and prognosis. Biomark Med. 2010;4:701&#x2013;712. doi: 10.2217/bmm.10.94.</Citation><ArticleIdList><ArticleId IdType="doi">10.2217/bmm.10.94</ArticleId><ArticleId IdType="pmc">PMC3049925</ArticleId><ArticleId IdType="pubmed">20945982</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu C.H., Macdonald-Wallis C., Gray E., Pearce N., Petzold A., Norgren N., Giovannoni G., Fratta P., Sidle K., Fish M., et al. Neurofilament light chain: A prognostic biomarker in amyotrophic lateral sclerosis. Neurology. 2015;84:2247&#x2013;2257. doi: 10.1212/WNL.0000000000001642.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000001642</ArticleId><ArticleId IdType="pmc">PMC4456658</ArticleId><ArticleId IdType="pubmed">25934855</ArticleId></ArticleIdList></Reference><Reference><Citation>Falzone Y.M., Russo T., Domi T., Pozzi L., Quattrini A., Filippi M., Riva N. Current application of neurofilaments in amyotrophic lateral sclerosis and future perspectives. Neural Regen. Res. 2021;16:1985&#x2013;1991.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8343335</ArticleId><ArticleId IdType="pubmed">33642372</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun J., Carrero J.J., Zagai U., Evans M., Ingre C., Pawitan Y., Fang F. Blood biomarkers and prognosis of amyotrophic lateral sclerosis. Eur. J. Neurol. 2020;27:2125&#x2013;2133. doi: 10.1111/ene.14409.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ene.14409</ArticleId><ArticleId IdType="pubmed">32557963</ArticleId></ArticleIdList></Reference><Reference><Citation>Lind A.-L., Wu D., Freyhult E., Bodolea C., Ekegren T., Larssson A., Gustafsson M.G., Katila L., Bergquist J., Gordh T., et al. A multiplex protein panel applied to cerebrospinal fluid reveals three new biomarker candidates in ALS but none in neuropathic pain patients. PLoS One. 2016;11:e0149821. doi: 10.1371/journal.pone.0149821.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0149821</ArticleId><ArticleId IdType="pmc">PMC4767403</ArticleId><ArticleId IdType="pubmed">26914813</ArticleId></ArticleIdList></Reference><Reference><Citation>Agah E., Saleh F., Moghaddam H.S., Saghazadeh A., Tafakhori A., Rezaei N. CSF and blood biomarkers in amyotrophic lateral sclerosis: Protocol for a systematic review and meta-analysis. Syst. Rev. 2018;7:237. doi: 10.1186/s13643-018-0913-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13643-018-0913-4</ArticleId><ArticleId IdType="pmc">PMC6300914</ArticleId><ArticleId IdType="pubmed">30572951</ArticleId></ArticleIdList></Reference><Reference><Citation>Staats K.A., Borchelt D.R., Tansey M.G., Wymer J. Blood-based biomarkers of inflammation in amyotrophic lateral sclerosis. Mol. Neurodegener. 2022;17:11. doi: 10.1186/s13024-022-00515-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13024-022-00515-1</ArticleId><ArticleId IdType="pmc">PMC8785449</ArticleId><ArticleId IdType="pubmed">35073950</ArticleId></ArticleIdList></Reference><Reference><Citation>Michnik A., Sadowska-Kr&#x119;pa E., Cholewa J., Schisler I., Kie&#x142;bo&#x144; A., Drzazga Z. Differential scanning calorimetry study of early and advanced stages in Parkinson&#x2019;s disease using human blood serum. Thermochim. Acta. 2018;662:64&#x2013;68. doi: 10.1016/j.tca.2018.02.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tca.2018.02.014</ArticleId></ArticleIdList></Reference><Reference><Citation>Garbett N.C., Miller J.J., Jenson A.B., Chairs J.B. Calorimetry Outside the Box: A New Window into the Plasma Proteome. Biophys. J. 2008;94:1377&#x2013;1383. doi: 10.1529/biophysj.107.119453.</Citation><ArticleIdList><ArticleId IdType="doi">10.1529/biophysj.107.119453</ArticleId><ArticleId IdType="pmc">PMC2212685</ArticleId><ArticleId IdType="pubmed">17951300</ArticleId></ArticleIdList></Reference><Reference><Citation>Garbett N.C., Mekmaysy C., Helm C.V., Jenson A.B., Chaires J.B. Differential scanning calorimetry of blood plasma for clinical diagnosis and monitoring. Exp. Mol. Pathol. 2009;86:186&#x2013;191. doi: 10.1016/j.yexmp.2008.12.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.yexmp.2008.12.001</ArticleId><ArticleId IdType="pubmed">19146849</ArticleId></ArticleIdList></Reference><Reference><Citation>Todinova S., Krumova S., Kurtev P., Dimitrov V., Djongov L., Dudunkov Z., Taneva S.G. Calorimetry-based profiling of blood plasma from colorectal cancer patients. Biochim. Biophys. Acta. 2012;1820:1879&#x2013;1885. doi: 10.1016/j.bbagen.2012.08.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbagen.2012.08.001</ArticleId><ArticleId IdType="pubmed">22903026</ArticleId></ArticleIdList></Reference><Reference><Citation>Krumova S., Todinova S., Taneva S.G. Calorimetric Markers for Detection and Monitoring of Multiple Myeloma. Cancers. 2022;14:3884. doi: 10.3390/cancers14163884.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cancers14163884</ArticleId><ArticleId IdType="pmc">PMC9405568</ArticleId><ArticleId IdType="pubmed">36010876</ArticleId></ArticleIdList></Reference><Reference><Citation>Fish D.J., Brewood G.P., Kim J.S., Garbett N.C., Chaires J.B., Benight A.S. Statistical analysis of plasma thermograms measured by differential scanning calorimetry. Biophys. Chem. 2010;152:184&#x2013;190. doi: 10.1016/j.bpc.2010.09.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bpc.2010.09.007</ArticleId><ArticleId IdType="pubmed">20961680</ArticleId></ArticleIdList></Reference><Reference><Citation>Garbett N.C., Merchant M.L., Helm C.W., Jenson A.B., Klein J.B., Chaires J.B. Detection of cervical cancer biomarker patterns in blood plasma and urine by differential scanning calorimetry and mass spectrometry. PLoS One. 2014;9:e84710. doi: 10.1371/journal.pone.0084710.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0084710</ArticleId><ArticleId IdType="pmc">PMC3885574</ArticleId><ArticleId IdType="pubmed">24416269</ArticleId></ArticleIdList></Reference><Reference><Citation>Todinova S., Krumova S., Gartcheva L., Robeerst C., Taneva S.G. Microcalorimetry of blood serum proteome: A modified interaction network in the multiple myeloma case. Anal. Chem. 2011;83:7992&#x2013;7998. doi: 10.1021/ac202055m.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/ac202055m</ArticleId><ArticleId IdType="pubmed">21928840</ArticleId></ArticleIdList></Reference><Reference><Citation>Zapf I., Fekecs T., Ferencz A., Tizedes G., Pavlovics G., K&#xe1;lm&#xe1;nd E., L&#x151;rinczy D. DSC analysis of human plasma in breast cancer patients. Thermochim. Acta. 2011;524:88&#x2013;91. doi: 10.1016/j.tca.2011.06.019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tca.2011.06.019</ArticleId></ArticleIdList></Reference><Reference><Citation>Fekecs T., Zapf I., Ferencz A., L&#x151;rinczy D. Differential scanning calorimetry (DSC) analysis of human plasma in melanoma patients with or without regional lymph node metastases. J. Therm. Anal. Calorim. 2012;108:149&#x2013;152. doi: 10.1007/s10973-011-1800-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10973-011-1800-6</ArticleId></ArticleIdList></Reference><Reference><Citation>Chagovetz A.A., Quinn C., Damarse N., Hansen L.D., Chagovetz A.M., Jensen R.L. Differential scanning calorimetry of gliomas: A new tool in brain cancer diagnostics? Neurosurgery. 2013;73:289&#x2013;295. doi: 10.1227/01.neu.0000430296.23799.cd.</Citation><ArticleIdList><ArticleId IdType="doi">10.1227/01.neu.0000430296.23799.cd</ArticleId><ArticleId IdType="pubmed">23624408</ArticleId></ArticleIdList></Reference><Reference><Citation>Vega S., Garcia-Gonzalez M.A., Lanas A., Velazquez-Campoy A., Abian O. Deconvolution analysis for classifying gastric adenocarcinoma patients based on differential scanning calorimetry serum thermograms. Sci. Rep. 2015;5:7988. doi: 10.1038/srep07988.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep07988</ArticleId><ArticleId IdType="pmc">PMC4303881</ArticleId><ArticleId IdType="pubmed">25614381</ArticleId></ArticleIdList></Reference><Reference><Citation>Velazquez-Campoy A., Vega S., Sanchez-Gracia O., Lanas A., Rodrigo A., Kaliappan A., Hall M.B., Nguyen T.Q., Brock G.N., Chesney J.A., et al. Thermal liquid biopsy for monitoring melanoma patients under surveillance during treatment: A pilot study. Biochim. Et Biophys. Acta-Gen. Subj. 2018;1862:1701&#x2013;1710. doi: 10.1016/j.bbagen.2018.04.020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbagen.2018.04.020</ArticleId><ArticleId IdType="pmc">PMC6483604</ArticleId><ArticleId IdType="pubmed">29705200</ArticleId></ArticleIdList></Reference><Reference><Citation>Farkas P., K&#xf6;ncz&#xf6;l F., L&#x151;rinczy D. Cyclophosphamide-induced changes in plasma and red blood cells detected by differential scanning calorimetry (DSC) in guinea pigs. J. Therm. Anal. Calorim. 2017;127:1239&#x2013;1243. doi: 10.1007/s10973-016-5442-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10973-016-5442-6</ArticleId></ArticleIdList></Reference><Reference><Citation>Farkas P., K&#xf6;ncz&#xf6;l F., L&#x151;rinczy D. Monitoring the side effects with DSC caused by cyclophosphamide. J. Therm. Anal. Calorim. 2020;142:765&#x2013;770. doi: 10.1007/s10973-019-09064-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10973-019-09064-0</ArticleId></ArticleIdList></Reference><Reference><Citation>Farkas P., Szam&#xe1;ri D., K&#xf6;ncz&#xf6;l F., L&#x151;rinczy D. Cyclophosphamide treatment evoked side effect on skeletal muscle actin, monitored by DSC. J. Therm. Anal. Calorim. 2022;147:3609&#x2013;3614. doi: 10.1007/s10973-021-10774-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10973-021-10774-7</ArticleId></ArticleIdList></Reference><Reference><Citation>L&#x151;rinczy D. Cyclophosphamide treatment evoked side effects on skeletal muscle monitored by DSC. J. Thermal Anal. Calorim. 2020;142:1897&#x2013;1901. doi: 10.1007/s10973-020-09388-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10973-020-09388-2</ArticleId></ArticleIdList></Reference><Reference><Citation>Garbett N.C., Mekmaysy C.S., DeLeeuw L., Chaires J.B. Clinical application of plasma thermograms. Utility, practical approaches and considerations. Methods. 2015;76:41&#x2013;50. doi: 10.1016/j.ymeth.2014.10.030.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ymeth.2014.10.030</ArticleId><ArticleId IdType="pmc">PMC4380532</ArticleId><ArticleId IdType="pubmed">25448297</ArticleId></ArticleIdList></Reference><Reference><Citation>Postuma R.B., Berg D., Stern M., Poewe W., Olanow C.W., Oertel W., Obeso J., Marek K., Litvan I., Lang A., et al. MDS clinical diagnostic criteria for Parkinson&#x2019;s disease. Mov. Disord. 2015;30:1591&#x2013;1601. doi: 10.1002/mds.26424.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mds.26424</ArticleId><ArticleId IdType="pubmed">26474316</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoehn M.M., Yahr M.D. Parkinsonism: Onset, progression and mortality. Neurology. 1967;17:427&#x2013;442. doi: 10.1212/WNL.17.5.427.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.17.5.427</ArticleId><ArticleId IdType="pubmed">6067254</ArticleId></ArticleIdList></Reference><Reference><Citation>Brooks B.R., Miller R.G., Swash M., Munsat T.L. World Federation of Neurology Research Group on Motor Neuron Diseases. El Escorial revisited: Revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph. Lateral Scler. Other Mot. Neuron Dis. 2000;1:293&#x2013;299. doi: 10.1080/146608200300079536.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/146608200300079536</ArticleId><ArticleId IdType="pubmed">11464847</ArticleId></ArticleIdList></Reference><Reference><Citation>Cedarbaum J.M., Stambler N., Malta E., Fuller C., Hilt D., Thurmond B., Nakanishi A. The ALSFRS-R: A revised ALS functional rating scale that incorporates assessments of respiratory function. BDNF ALS Study Group (Phase III) J. Neurol. Sci. 1999;169:13&#x2013;21. doi: 10.1016/S0022-510X(99)00210-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0022-510X(99)00210-5</ArticleId><ArticleId IdType="pubmed">10540002</ArticleId></ArticleIdList></Reference><Reference><Citation>Ryan M.T., Chopra R.K. Paradoxical effect of fatty-acid on steroid-albumin interaction. Biochim. Biophys. Acta. 1976;427:337&#x2013;349. doi: 10.1016/0005-2795(76)90309-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0005-2795(76)90309-3</ArticleId><ArticleId IdType="pubmed">1260006</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Connell T.X., Horita T.J., Kasvari B. Understanding and interpreting serum protein electrophoresis. Am. Fam. Physician. 2005;71:105&#x2013;112.</Citation><ArticleIdList><ArticleId IdType="pubmed">15663032</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>